Literature DB >> 20427084

Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.

A M Lynch1, J E Salmon.   

Abstract

The complement system protects the host against invading organisms, initiates inflammation and dispose of immune complexes and the products of inflammatory injury. The complement system provides an important link between the innate and adaptive immune systems. Experimental observations suggest that increased complement activation causes and/or perpetuates inflammation during pregnancy. Recent studies suggest a link between complement activation and preeclampsia. Excessive activation or insufficient regulation of complement recruits leukocytes and unleashes potent inflammatory and anti-angiogenic mediators associated with placental insufficiency and maternal endothelial dysfunction characteristic of preeclampsia. We review the animal and human studies that link complement activation and pathogenic events in preeclampsia, present evidence that activation of the complement system is associated with the development of preeclampsia and provides new targets to prevent its complications.

Entities:  

Mesh:

Year:  2010        PMID: 20427084      PMCID: PMC2900404          DOI: 10.1016/j.placenta.2010.03.010

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  103 in total

Review 1.  Pre-eclampsia: Is the immune maladaptation hypothesis still standing? An epidemiological update.

Authors:  Gus Dekker; Pierre-Yves Robillard
Journal:  J Reprod Immunol       Date:  2007-05-09       Impact factor: 4.054

2.  Cytotrophoblast induction of arterial apoptosis and lymphangiogenesis in an in vivo model of human placentation.

Authors:  Kristy Red-Horse; Jose Rivera; Andrea Schanz; Yan Zhou; Virginia Winn; Mirhan Kapidzic; Emin Maltepe; Kelly Okazaki; Ronit Kochman; Kim Chi Vo; Linda Giudice; Adrian Erlebacher; Joseph M McCune; Cheryl A Stoddart; Susan J Fisher
Journal:  J Clin Invest       Date:  2006-09-21       Impact factor: 14.808

3.  Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.

Authors:  Elena Goicoechea de Jorge; Claire L Harris; Jorge Esparza-Gordillo; Luis Carreras; Elena Aller Arranz; Cynthia Abarrategui Garrido; Margarita López-Trascasa; Pilar Sánchez-Corral; B Paul Morgan; Santiago Rodríguez de Córdoba
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

4.  Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies.

Authors:  Jaime M Shamonki; Jane E Salmon; Elizabeth Hyjek; Rebecca N Baergen
Journal:  Am J Obstet Gynecol       Date:  2007-02       Impact factor: 8.661

5.  How Does the maternal immune system contribute to the development of pre-eclampsia?

Authors:  A Moffett; S E Hiby
Journal:  Placenta       Date:  2007-02-08       Impact factor: 3.481

Review 6.  Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.

Authors:  Anna Richards; David Kavanagh; John P Atkinson
Journal:  Adv Immunol       Date:  2007       Impact factor: 3.543

7.  Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.

Authors:  Celia J Fang; Veronique Fremeaux-Bacchi; M Kathryn Liszewski; Gaia Pianetti; Marina Noris; Timothy H J Goodship; John P Atkinson
Journal:  Blood       Date:  2007-10-03       Impact factor: 22.113

8.  Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury.

Authors:  Patricia Redecha; Rachel Tilley; Michael Tencati; Jane E Salmon; Daniel Kirchhofer; Nigel Mackman; Guillermina Girardi
Journal:  Blood       Date:  2007-05-29       Impact factor: 22.113

9.  Inflammation and dyslipidemia related to risk of spontaneous preterm birth.

Authors:  Janet M Catov; Lisa M Bodnar; Roberta B Ness; Stacy J Barron; James M Roberts
Journal:  Am J Epidemiol       Date:  2007-09-30       Impact factor: 4.897

10.  Hypertension and maternal-fetal conflict during placental malaria.

Authors:  Atis Muehlenbachs; Theonest K Mutabingwa; Sally Edmonds; Michal Fried; Patrick E Duffy
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

View more
  44 in total

1.  Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.

Authors:  Kathryn E Lillegard; Alex C Loeks-Johnson; Jonathan W Opacich; Jenna M Peterson; Ashley J Bauer; Barbara J Elmquist; Ronald R Regal; Jeffrey S Gilbert; Jean F Regal
Journal:  J Pharmacol Exp Ther       Date:  2014-08-22       Impact factor: 4.030

2.  Effect of nicotine on placental ischemia-induced complement activation and hypertension in the rat.

Authors:  Connor F Laule; Cameron R Wing; Evan J Odean; Jacob A Wilcox; Jeffrey S Gilbert; Jean F Regal
Journal:  J Immunotoxicol       Date:  2017-12       Impact factor: 3.000

Review 3.  CD46 in innate and adaptive immunity: an update.

Authors:  J Cardone; G Le Friec; C Kemper
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

Review 4.  Emerging Treatment Models in Rheumatology: Antiphospholipid Syndrome and Pregnancy: Pathogenesis to Translation.

Authors:  Vikki M Abrahams; Lawrence W Chamley; Jane E Salmon
Journal:  Arthritis Rheumatol       Date:  2017-07-18       Impact factor: 10.995

5.  The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia.

Authors:  Anne M Lynch; Brandie D Wagner; Patricia C Giclas; Nancy A West; Ronald S Gibbs; V Michael Holers
Journal:  Am J Reprod Immunol       Date:  2015-10-29       Impact factor: 3.886

6.  Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells.

Authors:  Manu Banadakoppa; Meena Balakrishnan; Chandra Yallampalli
Journal:  Am J Reprod Immunol       Date:  2018-08-12       Impact factor: 3.886

7.  Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.

Authors:  Eleazar Soto; Roberto Romero; Juan Pedro Kusanovic; Giovanna Ogge; Youssef Hussein; Lami Yeo; Sonia S Hassan; Chong Jai Kim; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-25

8.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Authors:  Selene Nunez-Cruz; Phyllis A Gimotty; Matthew W Guerra; Denise C Connolly; You-Qiang Wu; Robert A DeAngelis; John D Lambris; George Coukos; Nathalie Scholler
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

9.  Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.

Authors:  Mimi Y Kim; Marta M Guerra; Elianna Kaplowitz; Carl A Laskin; Michelle Petri; D Ware Branch; Michael D Lockshin; Lisa R Sammaritano; Joan T Merrill; T Flint Porter; Allen Sawitzke; Anne M Lynch; Jill P Buyon; Jane E Salmon
Journal:  Ann Rheum Dis       Date:  2018-01-25       Impact factor: 19.103

10.  Complement activation is critical for placental ischemia-induced hypertension in the rat.

Authors:  Kathryn E Lillegard; Alex C Johnson; Sarah J Lojovich; Ashley J Bauer; Henry C Marsh; Jeffrey S Gilbert; Jean F Regal
Journal:  Mol Immunol       Date:  2013-05-15       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.